Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage

Alessandra Ianari, Rita Gallo, Marzia Palma, Edoardo Alesse, Alberto Gulino

Research output: Contribution to journalArticle

Abstract

E2F1, a member of the E2F family of transcription factors, plays a pivotal role in controlling both physiological cell-cycle progression and apoptotic cell death in response to DNA damage and oncogene activation. In response to genotoxic stresses, E2F1 is stabilized by signals that include ATM-dependent phosphorylation. We recently demonstrated that DNA damage induces also E2F1 acetylation, which is required for its recruitment onto apoptotic gene promoters. Here we show that E2F1 is stabilized in response to doxorubicin and cisplatin treatments even in the absence of either ATM-dependent phosphorylation or p53 and cAbl, two major transducers of DNA damage signaling. We found that acetylation of E2F1 is, instead, required to stabilize the protein in response to doxorubicin. Finally, we report that the formation of E2F1-p300/CREB-binding protein-associated factor (P/CAF) complexes is preferentially induced in doxorubicin-treated cells, and that P/CAF acetyltransferase (HAT), but not p300 HAT activity, is required for a significant E2F1 stabilization and accumulation. Our results unveil a differential role of P/CAF and p300 in acetylation-induced stabilization of E2F1, thus supporting a specific role for P/CAF HAT activity in E2F1-dependent apoptosis in response to DNA damage.

Original languageEnglish
Pages (from-to)30830-30835
Number of pages6
JournalJournal of Biological Chemistry
Volume279
Issue number29
DOIs
Publication statusPublished - Jul 16 2004

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry

Cite this